Backsdime, a bio R&D specialized company, announced on the 14th that it was finally selected as the main R&D institution for the 2025 Seoul-type R&D Bio-Medical Technology Commercialization Support Project, hosted by the Seoul Metropolitan Government and operated by the Seoul Economic Promotion Agency (SBA).
This project will be funded by a total of 530 million won, of which 400 million won has been allocated as government subsidy. Baxdime will conduct research aimed at "developing AI-powered mid-molecule drug candidates and developing a delivery platform process based on the NC-LS fusion structure." The main objectives of this project are to explore advanced biomaterial candidates using artificial intelligence (AI) and develop novel delivery technology.
Baxdime CEO Kim Seong-jae introduced the characteristics of NC and LS proteins, which are based on the company's original technology, Chaperna. He explained that NC (Nucleocapsid) protein has excellent stability in binding to target proteins, while LS (Lumazine Synthase) has self-assembly properties and metabolic pathway-related functions. He went on to emphasize that the two proteins can be fused to create a water-soluble particle-type carrier, which can improve the stability, tissue delivery efficiency, and targeting action of mid-molecule drugs in the body.
Chapena technology is known as a platform for the low-cost, high-efficiency production of peptides and proteins using microorganisms. It rapidly synthesizes complex proteins, simplifies the production process, and reduces costs. It is considered highly expandable across diverse industries, including pharmaceuticals, medical devices, functional cosmetics, and health functional foods.
Through this project, Baxdime plans to accelerate AI-based candidate material discovery and become the first in Korea to build a self-assembly delivery platform based on NC-LS fusion polymers, reaching the production process stage. Furthermore, the technology will be expanded to develop next-generation biomaterials based on functional peptides and proteins.
This research is being conducted through a collaborative industry-academia partnership between Pobio Korea and the Sungshin Women's University Research Industry-Academic Collaboration Foundation. Pobio Korea will be responsible for the AI-based discovery and validation of mid-molecule drug targets, while the Sungshin Women's University Research Industry-Academic Collaboration Foundation will be responsible for the development of NC-LS-based particle structure technology and efficacy evaluation. Based on this collaboration, Baxdime plans to develop cell lines for mid-molecule drug production and standardize quality assessment.
CEO Kim Seong-jae said, “We will create a turning point for the development of advanced domestic biomaterials through AI and innovative protein fusion technology,” and “Based on collaboration with our joint research team, we will accelerate the development and commercialization of new technologies with global competitiveness.”
- See more related articles
You must be logged in to post a comment.